ProCE Banner Activity

How Data From IAS 2019 on Dual Therapy May Soon Affect ART Guidelines

Conference Coverage
Clinical Thought
Updated first-line and switch data reinforce the noninferiority of DTG/3TC compared with 3-drug regimens. How will these results affect practice? Here’s my take.

Released: August 20, 2019

Expiration: August 18, 2020

Share

Faculty

Jurgen Rockstroh

Jurgen Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
Department of Medicine I
University Hospital Bonn
Bonn, Germany  

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Educational grant provided by:

Gilead

Partners

IAS 2018

ProCE Banner

IAS 2019

ProCE Banner

Faculty Disclosure

Primary Author

Jurgen Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
Department of Medicine I
University Hospital Bonn
Bonn, Germany  

Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abivax, Gilead Sciences, Janssen, Merck, and ViiV Healthcare and funds for non-CME/CE services from Gilead Sciences, Janssen, Merck, and ViiV Healthcare.